- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Neal Dave, PharmD, Discusses the Importance of Consistently Reevaluating the Cost-Effectiveness of Biosimilars
Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, talks about the importance of conducting regular evaluations to ensure that prescribing the most cost-effective option, whether that be a biosimilar or the reference product.
Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, talks about the importance of conducting regular evaluations to ensure that prescribing the most cost-effective option, whether that be a biosimilar or the reference product.
Transcript:
Could you explain some of the price declines that we've seen among oncology biosimilars and the significance of this?
Yeah, it's so important to measure. So, we switched our patients that were on Procrit [epoetin alfa] over to the biosimilar because of the cost savings. But it's important to realize that you do need to reevaluate where you are with which product that you're using because the prices can change. And so, just because it's a biosimilar and maybe when it was first released, it was the lowest cost product, that doesn't mean that it's going to stay that way.
Even the prices of the [reference] drugs are coming down. So, it's important to reevaluate that from time to time, whatever your cadence is, to ensure that what you're using is still actually cost-effective and that you're not actually increasing cost of care.
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches
March 28th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Read More
